[18F]AlF-NOTA-FAPI PET/CT指导I-IIIC期肺癌放疗计划的价值:与增强CT和[18F]FDG PET/CT的比较
该研究为前瞻性试验的二次分析,纳入51例I-III期肺癌患者,比较基于增强CT、[18F]AlF-NOTA-FAPI PET/CT和[18F]FDG PET/CT勾画的大体肿瘤体积(GTV)及制定的调强放疗(IMRT)和调强质子治疗(IMPT)计划。结果显示各模态GTV间多存在显著差异,基于CE-CT的GTVp因阻塞性肺炎(n=18)显著大于两种PET/CT;基于FAPI的IMRT计划PTVall显著小于CE-CT,且IMRT计划中心脏、对侧肺和双肺剂量显著降低。结论认为[18F]AlF-NOTA-FAPI PET/CT在肺癌放疗计划中具有提供准确靶区勾画和改善危及器官保护的潜力。
要点
- 基于CE-CT的GTVp因阻塞性肺炎(n=18)显著大于[18F]FDG和[18F]AlF-NOTA-FAPI PET/CT。
- 基于FAPI的IMRT计划PTVall(329.98 ± 26.21)显著小于CE-CT(351.98 ± 26.87;P=0.03)。
- 基于FAPI的IMRT计划显著降低心脏、对侧肺和双肺的辐射剂量(均P<0.05)。
核心结论
- [18F]AlF-NOTA-FAPI PET/CT在肺癌放疗计划中有望提供准确靶区勾画并改善危及器官保护。
研究设计与样本
- 前瞻性试验的二次分析,纳入51例I-III期肺癌患者(中位年龄64岁;男性38例[74.5%]),在2周内完成[18F]AlF-NOTA-FAPI与CE-CT或[18F]FDG PET/CT扫描。
- 基于CE-CT、[18F]AlF-NOTA-FAPI PET/CT和[18F]FDG PET/CT分别勾画原发肿瘤(GTVp)和受累淋巴结(GTVnd)的GTV、CTV和PTV,并比较IMRT和IMPT计划中的危及器官。
主要发现
- CE-CT、[18F]AlF-NOTA-FAPI PET/CT和[18F]FDG PET/CT两两比较的GTVs均存在统计学显著差异(均P<0.05),但[18F]AlF-NOTA-FAPI与[18F]FDG PET/CT的GTVp无差异(P=0.558)。
- 因阻塞性肺炎(n=18),基于CE-CT的GTVp显著大于基于[18F]FDG PET/CT和[18F]AlF-NOTA-FAPI PET/CT(均P<0.05)。
- 基于CE-CT的PTVall-IMRT(351.98 ± 26.87)显著大于基于[18F]AlF-NOTA-FAPI PET/CT(329.98 ± 26.21;P=0.03)。
- 基于CE-CT的PTVall-IMPT(212.74 ± 18.73)显著大于基于[18F]FDG PET/CT(204.26 ± 19.34)和[18F]AlF-NOTA-FAPI PET/CT(196.99 ± 18.38),P值分别为0.046和0.011。
- 对于IMRT,基于[18F]AlF-NOTA-FAPI PET/CT的计划显著降低心脏、对侧肺和双肺的辐射剂量(均P<0.05)。
临床怎么用
- 在肺癌放疗计划中,可考虑使用[18F]AlF-NOTA-FAPI PET/CT辅助靶区勾画,以减少阻塞性肺炎对GTVp的影响并降低IMRT计划中心脏和肺的剂量。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To evaluate the usefulness of [18F]AlF-labeled fibroblast activation protein inhibitor (FAPI), chelated with NOTA (denoted as [18F]AlF-NOTA-FAPI), positron emission tomography/computed tomography (PET/CT) for radiotherapy planning in lung cancer, we compared it with contrast-enhanced CT (CE-CT) and [18F]FDG PET/CT. MATERIALS AND METHODS: In this secondary analysis of a prospective trial, patients with stage I-III lung cancer who underwent [18F]AlF-NOTA-FAPI and CE-CT or [18F]FDG PET/CT scans within 2 weeks were selected. Gross tumor volume (GTV), clinical tumor volume (CTV), and planning tumor volume (PTV) were drawn for the primary tumor (GTVp) and involved lymph nodes (GTVnd) based on CE-CT, [18F]AlF-NOTA-FAPI PET/CT and [18F]FDG PET/CT. Organs at risk were evaluated and compared in intensity-modulated radiation therapy (IMRT) and intensity-modulated proton therapy (IMPT) plans. RESULTS: Fifty-one patients (median age, 64 years; 38 males [74.5%]) were evaluated. Statistically significant differences in GTVs based on CE-CT, [18F]AlF-NOTA-FAPI PET/CT, and [18F]FDG PET/CT were found between each pair (all P < 0.05), except that no difference in GTVp was found between [18F]AlF-NOTA-FAPI and [18F]FDG PET/CT (P = 0.558). CE-CT-based GTVp values were significantly larger than those based on [18F]FDG PET/CT and [18F]AlF-NOTA-FAPI PET/CT due to the presence of obstructive pneumonia (n = 18; all P < 0.05). PTVall-IMRT based on CE-CT (351.98 ± 26.87) was significantly larger than that based on [18F]AlF-NOTA-FAPI PET/CT (329.98 ± 26.21; P = 0.03). PTVall-IMPT based on CE-CT (212.74 ± 18.73) was significantly larger than those based on [18F]FDG PET/CT (204.26 ± 19.34) and [18F]AlF-NOTA-FAPI PET/CT (196.99 ± 18.38), with P-values of 0.046 and 0.011, respectively. For IMRT, [18F]AlF-NOTA-FAPI PET/CT-based plans significantly reduced the radiation doses received by the heart, contralateral lung, and both lungs (all P < 0.05). CONCLUSION: [18F]AlF-NOTA-FAPI PET/CT shows promise as a valuable tool for radiotherapy planning in lung cancer, providing accurate target delineation and improved sparing of critical organs. TRIAL REGISTRATION: This study was approved by the Clinical Research Ethics Committee of our institution.
引用
- Qin J, Li C, Huang Y, et al. Value of [18F]AlF-NOTA-FAPI PET/CT in guiding radiotherapy planning for stage I-IIIC lung cancer: A comparison with contrast-enhanced CT and [18F]FDG PET/CT. Eur J Nucl Med Mol Imaging. 2026. PMID: 41639223. doi:10.1007/s00259-025-07753-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。